Ibrutinib: Is it best used early in treatment, or after other treatment options have failed?

[bkoffman]

#CLLSociety During ASH 2019, our own Dr. Brian Koffman interviewed Dr. Paul Barr, Associate Professor of Medicine at the Wilmot Cancer Institute, in Rochester, NY, where they discussed a new analysis of clinical trial data that looks at how effective ibrutinib is depending on when it is used in a patient’s course of therapy. Is the best time to use it early on in treatment, or after other treatment options have failed? A post-hoc analysis of the RESONATE and RESONATE 2 studies were used. Watch the interview here. cllsociety.org/2020/11/ash-...

[Reddg]

Thank you for this post, very interesting. I started Ibrutinib as my first line treatment in the UK

[W00dfin]

At the end of 5 years in FCR remission I was started on Ibrutinib. After enduring episodic joint pain, brittle nails and excessive bruising for 3+ years I had to stop Ibrutinib due to afib one year ago. Since then I have been followed on no treatment other than IVIG. My last CBC and CMP showed all counts within normal range. Also had a low count on a flow cytometry which measures the number of bad guys in your bloodstream.

So Ibrutinib following another treatment has worked for me.

[Milla15]

I think I'm missing something here. Wouldn't PFS drop naturally the more previous treatments experienced because you would be dealing with more refractory disease?

[bkoffman CLL CURE Hero in reply to Milla15]

That makes sense and the the data now prove it